BSE · 512600
Astal Laboratories Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹40 Cr with net profit ₹4 Cr — a 9.39% net margin, versus 5.88% the period before.
Shareholding
As of 2026-09-30
- Promoter4.59%
- Public95.41%
3,351 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.67× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #62 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,22,523 Cr | 33.44 | 5.06 | 13.74% | 20.29% |
| Laurus Labs Limited | ₹1,21,246 Cr | 110.87 | 22.88 | 16.77% | 15.04% |
| Zydus Lifesciences Ltd. | ₹1,18,144 Cr | 24.2 | 4.36 | 18.59% | 16.09% |
| Dr Reddys Laboratories Ltd. | ₹1,12,265 Cr | 40.1 | 2.89 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,09,709 Cr | 35.33 | 3.1 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,01,993 Cr | 43.71 | 5.8 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹95,507 Cr | 25.26 | 2.52 | 9.25% | 10.7% |
| Lupin Limited | ₹90,997 Cr | 15.28 | 4.05 | 23.76% | 18.72% |
| Glenmark Pharmaceuticals Ltd. | ₹66,012 Cr | 21.15 | 6.28 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹60,727 Cr | 26.65 | 4.39 | 16.66% | 14.31% |
| Astal Laboratories Limited(this company) | ₹276 Cr | 18.77 | 0.82 | 4.41% | 7.15% |
AI analysis
AI-generated · google/gemini-2.5-flashAstal Laboratories Limited reported a market capitalization of Rs 359 Cr. The company's revenue stood at Rs 64.36 Cr, with a profit margin of 0%. The earnings per share (EPS) was Rs 3.36.
Positives
- +The debt-to-equity ratio is low at 0.23.
- +The return on equity (ROE) is high at 440.7%.
Negatives
- −The profit margin is 0%, indicating no profit relative to revenue.
- −Promoter holding is extremely low at 4.5334% as of June 30, 2026.
- −The company does not pay a dividend, with a dividend yield of 0%.
Financial Performance
For the fiscal year ending March 2025, Astal Laboratories Limited generated a revenue of Rs 64.3561 Cr and a net profit of Rs 8.9253 Cr. Quarterly results show varying performance, with revenue reaching Rs 134.05 Cr and net profit at Rs 7.68 Cr in March 2026, compared to Rs 52.24 Cr revenue and Rs 2.36 Cr net profit in December 2025.
Profitability & Returns
The company's return on equity (ROE) was 440.7% and return on capital employed (ROCE) was 5.1513%. The profit margin currently stands at 0%. Earnings per share (EPS) for the latest period was Rs 3.36, with an annual EPS of Rs 8.043 in March 2025.
Balance Sheet
Astal Laboratories Limited has a debt-to-equity ratio of 0.23, indicating a low reliance on debt financing. The book value per share was Rs 77.65.
Ownership & Pledges
As of June 30, 2026, promoter holding in Astal Laboratories Limited was 4.5334%, while public shareholding was 95.4666%. There were no shares pledged by the promoters. The number of shareholders was 3274.
Data as of — price: 2026-10-29 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Astal Laboratories Limitedshare price & fundamentals